Oculis Holding AG (OCS) | Financial Analysis & Statements
Oculis Holding AG Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-20.6M
Net Income
-23.5M
EPS (Diluted)
$-0.42
Balance Sheet Metrics
Total Assets
236.0M
Total Liabilities
39.9M
Shareholders Equity
196.1M
Debt to Equity
0.20
Cash Flow Metrics
Operating Cash Flow
-19.9M
Free Cash Flow
-16.7M
Revenue & Profitability Trend
Oculis Holding AG Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 57.1M | 52.1M | 29.2M | 22.2M | 9.6M |
| Selling, General & Administrative | 23.2M | 18.9M | 14.7M | 6.7M | 4.1M |
| Other Operating Expenses | 1.2M | 2.1M | 1.8M | 3.3M | -482.0K |
| Total Operating Expenses | 81.5M | 73.1M | 45.8M | 32.3M | 13.2M |
| Operating Income | -81.7M | -73.2M | -45.9M | -32.4M | -13.2M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 1.8M | 2.2M | 1.4M | 126.0K | 21.0K |
| Interest Expense | 833.0K | 639.0K | 1.3M | 6.4M | 5.1M |
| Other Non-Operating Income | -18.4M | -14.3M | -43.0M | 49.0K | -193.0K |
| Pre-tax Income | -99.1M | -85.9M | -88.7M | -38.6M | -18.5M |
| Income Tax | -186.0K | -160.0K | 107.0K | 55.0K | 27.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -99.0M | -85.8M | -88.8M | -38.7M | -18.6M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -79.4M | -70.6M | -44.1M | -32.0M | -13.0M |
| EPS (Basic) | $-1.89 | $-2.12 | $-2.97 | $-1.18 | $-0.57 |
| EPS (Diluted) | $-1.89 | $-2.12 | $-2.97 | $-1.18 | $-0.57 |
| Basic Shares Outstanding | 52358201 | 40406551 | 26410372 | 29410936 | 29410936 |
| Diluted Shares Outstanding | 52358201 | 40406551 | 26410372 | 29410936 | 29410936 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Oculis Holding AG Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 81.3M | 27.7M | 38.3M | 19.8M | 46.3M |
| Short-term Investments | 131.7M | 71.0M | 53.3M | 0 | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 218.9M | 104.9M | 101.0M | 23.7M | 48.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 3.2M | 1.9M | 1.4M | 1.4M | 1.4M |
| Goodwill | 13.3M | 13.3M | 12.2M | 12.2M | 8.7M |
| Intangible Assets | 13.3M | 13.3M | 12.2M | 12.2M | 8.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 785.0K | 476.0K | 89.0K | 98.0K | -1.0K |
| Total Non-Current Assets | 17.1M | 15.5M | 13.3M | 13.4M | 10.1M |
| Total Assets | 236.0M | 120.4M | 114.4M | 37.1M | 58.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.8M | 5.9M | 7.6M | 3.9M | 824.0K |
| Short-term Debt | 502.0K | 315.0K | 174.0K | 142.0K | 193.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 14.5M | 19.9M | 5.4M | 1.0K | - |
| Total Current Liabilities | 36.7M | 44.2M | 19.1M | 12.0M | 4.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.8M | 865.0K | 431.0K | 491.0K | 577.0K |
| Deferred Tax Liabilities | - | - | - | 0 | 11.0K |
| Other Non-Current Liabilities | - | - | - | 122.4M | 113.5M |
| Total Non-Current Liabilities | 3.1M | 2.7M | 1.5M | 123.0M | 114.9M |
| Total Liabilities | 39.9M | 47.0M | 20.6M | 135.1M | 119.0M |
| Equity | |||||
| Common Stock | 587.0K | 446.0K | 366.0K | 39.0K | 335.0K |
| Retained Earnings | -384.5M | -285.6M | -199.8M | -111.0M | -72.3M |
| Treasury Stock | 7.0K | 10.0K | 0 | 1.0K | 100.0K |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 196.1M | 73.4M | 93.7M | -98.0M | -61.0M |
| Key Metrics | |||||
| Total Debt | 2.3M | 1.2M | 605.0K | 633.0K | 770.0K |
| Working Capital | 182.1M | 60.7M | 81.9M | 11.6M | 43.9M |
Balance Sheet Composition
Oculis Holding AG Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -99.1M | -85.9M | -88.7M | -38.6M | -18.5M |
| Depreciation & Amortization | 546.0K | 406.0K | 287.0K | 299.0K | 235.0K |
| Stock-Based Compensation | 16.0M | 9.8M | 3.6M | 804.0K | 328.0K |
| Working Capital Changes | -74.0K | 3.4M | -1.8M | 1.1M | -439.0K |
| Operating Cash Flow | -78.6M | -75.0M | -47.0M | -30.6M | -12.4M |
| Investing Activities | |||||
| Capital Expenditures | -301.0K | -230.0K | -48.0K | -65.0K | -28.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -60.8M | -17.3M | -54.2M | 0 | 0 |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -61.1M | -17.6M | -54.2M | -65.0K | -28.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | 0 | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -373.0K | -274.0K | -158.0K | -159.0K | -98.0K |
| Financing Cash Flow | 165.3M | 50.4M | 127.9M | 1.6M | 55.2M |
| Free Cash Flow | -67.7M | -47.7M | -53.9M | -28.6M | -13.9M |
| Net Change in Cash | 25.5M | -42.2M | 26.7M | -29.0M | 42.7M |
Cash Flow Trend
Oculis Holding AG Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
63.63
Forward P/E
-12.86
Price to Book
6.45
Price to Sales
1,346.84
PEG Ratio
-1.71
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-5,020.20%
Return on Equity
-73.45%
Return on Assets
-28.65%
Financial Health
Current Ratio
5.96
Debt to Equity
1.18
Beta
0.21
Per Share Data
EPS (TTM)
$-2.43
Book Value per Share
$4.32
Revenue per Share
$0.02
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| OCS | 1.6B | 63.63 | 6.45 | -73.45% | 0.00% | 1.18 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






